A single-blind study was conducted to investigate the effect of multiple doses of finasteride, a 5 alpha-reductase inhibitor for the treatment of benign prostatic hyperplasia, on the single-dose pharmacokinetics of antipyrine. Twelve patients with benign prostatic hyperplasia received a total of four single oral doses of 18 mg/kg antipyrine before, during, and after treatment with 10 mg/day of finasteride for 28 days. Finasteride had no effect on antipyrine concentration profiles. There were also no changes in urinary excretion of three principal antipyrine metabolites. A slight increase in renal clearance of antipyrine was observed; however, this is not considered relevant because excretion of unchanged antipyrine represents a minor fraction of total elimination and is not directly related to oxidative metabolism. These results imply that significant interactions between finasteride and drugs metabolized by these cytochrome P-450 enzymes are unlikely.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/j.1552-4604.1993.tb01931.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial comment on "Dutasteride, a 5 alpha-reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia".
Int J Urol
January 2025
Department of Urology, Osaka City General Hospital, Osaka, Osaka, Japan.
The latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia.
Expert Opin Pharmacother
January 2025
Department of Urology, Sismanoglio General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: BPH/male LUTS is a prevalent condition in the aging male population with multifactorial pathophysiology. Pharmacotherapy remains the cornerstone of treatment in patients who fail conservative treatment. 5-α-Reductase inhibitors (5-ARIs) are the only class of medication shown to reduce the risk of acute retention and BPH-related surgery and, thus, are commonly used along with other "short acting" medications in combination treatments.
View Article and Find Full Text PDFComparative study between fractional CO2 laser alone versus fractional CO2 laser combined with topical dutasteride in treatment of male androgenic alopecia.
Lasers Med Sci
January 2025
Dermatology and Venereology Department, Faculty of Medicine (Girls), Al-Azhar University, 53, New Cairo, 3rd Zone Fifth, Settlement, Cairo, Egypt.
Androgenic alopecia (AGA) is the most common form of non-scarring hair loss, characterized by marked hair follicle miniaturization. AGA is a challenging skin condition with limited treatment results. Laser light can promote hair growth at specific wavelengths.
View Article and Find Full Text PDFCorrelation between Androgentic Alopecia and Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection in China.
J Invest Dermatol
December 2024
Department of Dermatology, China-Japan Friendship Hospital, Beijing, China. Electronic address:
With the widespread prevalence of COVID-19, researchers have suggested a potential link between androgens and COVID-19 outcomes. However, the relationship between COVID-19 and androgenetic alopecia (AGA)-a condition strongly influenced by androgens-remains controversial in existing studies. Notably, there is a lack of large-scale clinical studies, particularly concerning data on the Chinese population after infection with the Omicron variant.
View Article and Find Full Text PDFUsing 5 alpha reductase inhibitors safely: What primary care physicians need to know.
J Family Med Prim Care
November 2024
Department of Medicine, University of Florida, Gainesville, USA.
5 Alpha Reductase Inhibitor (ARI) is a widely used class of medication; for benign prostatic hypertrophy, androgenetic alopecia and hirsutism. While generally considered safe, ARIs class of medication does have a number of side effects, which can sometimes persist long after discontinuation of the medication. Since this class of medication is generally thought of as being benign, it can be overlooked as a potential cause of new clinical symptoms patients might experience.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!